Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
15. September 2020 07:00 ET
|
Novavax, Inc.
Serum Institute of India to manufacture ~1 billion doses of NVX-CoV2373 in 2021Increases global manufacturing capacity for NVX-CoV2373 to over 2 billion annualized doses when at full capacity in...
Novavax to Participate in Upcoming Investor Conferences
10. September 2020 07:00 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax Announces Publication of Phase 1 Data for COVID-19 Vaccine Candidate in The New England Journal of Medicine
02. September 2020 17:14 ET
|
Novavax, Inc.
GAITHERSBURG, Md., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax and Canada Reach Agreement in Principle to Acquire Novavax’ COVID-19 Vaccine
31. August 2020 08:55 ET
|
Novavax, Inc.
• Canadian government to purchase up to 76 million doses of NVX-CoV2373 GAITHERSBURG, Md., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company...
Novavax Initiates Phase 2 Portion of Phase 1/2 Clinical Trial of COVID-19 Vaccine
24. August 2020 09:00 ET
|
Novavax, Inc.
Primary objectives expand evaluation of immunogenicity and safetySecondary objectives include preliminary efficacy assessmentTrial to enroll up to 1,500 volunteers in United States and Australia, with...
Novavax Initiates Efficacy Trial of COVID-19 Vaccine in South Africa
17. August 2020 02:30 ET
|
Novavax, Inc.
Phase 2b clinical trial in collaboration with Professor Shabir Madhi and Wits UniversityBill & Melinda Gates Foundation providing $15 million grant toward trialMature trial infrastructure along...
Novavax and UK Government Announce Collaboration and Purchase Agreement for Novavax’ COVID-19 Vaccine Candidate
14. August 2020 01:07 ET
|
Novavax, Inc.
UK government to purchase 60 million doses of NVX-CoV2373Novavax to partner with FUJIFILM Diosynth Biotechnologies to manufacture antigen component of NVX-CoV2373 in the UKNovavax and UK government to...
Novavax and SK bioscience Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate
13. August 2020 08:30 ET
|
Novavax, Inc.
SK bioscience to manufacture antigen component of NVX-CoV2373Builds on and complements Novavax-CEPI collaboration to develop and distribute NVX-CoV2373Novavax, SK bioscience and Republic of Korea...
Novavax Reports Second Quarter 2020 Financial and Operational Results
10. August 2020 16:02 ET
|
Novavax, Inc.
Announced Positive Phase 1 data of Phase 1/2 clinical trial of NVX-CoV2373Secured $2 billion in funding for global coronavirus vaccine program through CEPI, DoD, and OWSExpanded large scale global...
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
07. August 2020 05:26 ET
|
Novavax, Inc.
Novavax will license COVID-19 vaccine technology to Takeda for local production and commercialization in JapanMatrix-M adjuvant to be supplied from NovavaxGovernment of Japan will provide funding to...